Mektovi Dosage

Generic name: BINIMETINIB 15mg
Dosage form: tablet, film coated
Drug class: Multikinase inhibitors

Medically reviewed by Drugs.com. Last updated on Mar 20, 2025.

Patient Selection

BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma

Confirm the presence of a BRAF V600E or V600K mutation in tumor specimens prior to initiating MEKTOVI. Do not take a missed dose of MEKTOVI within 6 hours of the next dose of MEKTOVI.

Do not take an additional dose if vomiting occurs after MEKTOVI administration but continue with the next scheduled dose.

Dosage Modifications for Adverse Reactions

If encorafenib is permanently discontinued, discontinue MEKTOVI.

Dose reductions for adverse reactions associated with MEKTOVI are presented in Table 1.

Table 1: Recommended Dose Reductions for MEKTOVI for Adverse Reactions
Action	Recommended Dose
First Dose Reduction	30 mg orally twice daily
Subsequent Modification	Permanently discontinue if unable to tolerate MEKTOVI 30 mg orally twice daily

Dosage modifications for adverse reactions associated with MEKTOVI are presented in Table 2.

Table 2: Recommended Dosage Modifications for MEKTOVI for Adverse Reactions
Severity of Adverse Reaction*	Dose Modification for MEKTOVI
* National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. † Dose modification of MEKTOVI when administered with encorafenib is not recommended for the following adverse reactions: palmar-plantar erythrodysesthesia syndrome (PPES), non-cutaneous RAS mutation-positive malignancies, and QTc prolongation.
Cardiomyopathy
• Asymptomatic, absolute decrease in LVEF of greater than 10% from baseline that is also below lower limit of normal (LLN)	Withhold MEKTOVI for up to 4 weeks, evaluate LVEF every 2 weeks. Resume MEKTOVI at a reduced dose if the following are present: • LVEF is at or above the lower limit of normal and • Absolute decrease from baseline is 10% or less and • Patient is asymptomatic. If the LVEF does not recover within 4 weeks permanently discontinue MEKTOVI.
• Symptomatic congestive heart failure or absolute decrease in LVEF of greater than 20% from baseline that is also below LLN	Permanently discontinue MEKTOVI.
Venous Thromboembolism
• Uncomplicated deep venous thrombosis (DVT) or pulmonary embolism (PE)	Withhold MEKTOVI. • If improves to Grade 0-1, resume at a reduced dose. • If no improvement, permanently discontinue MEKTOVI.
• Life threatening PE	Permanently discontinue MEKTOVI.
Serous Retinopathy
• Symptomatic serous retinopathy/Retinal pigment epithelial detachments	Withhold MEKTOVI for up to 10 days. • If improves and becomes asymptomatic, resume at same dose. • If not improved, resume at a lower dose level or permanently discontinue MEKTOVI.
Retinal Vein Occlusion (RVO)
• Any Grade	Permanently discontinue MEKTOVI.
Uveitis
• Grade 1-3	If Grade 1 or 2 does not respond to specific ocular therapy, or for Grade 3 uveitis, withhold MEKTOVI for up to 6 weeks. • If improved, resume at same or reduced dose. • If not improved, permanently discontinue MEKTOVI.
• Grade 4	Permanently discontinue MEKTOVI.
Interstitial Lung Disease
• Grade 2	Withhold MEKTOVI for up to 4 weeks. • If improved to Grade 0-1, resume at a reduced dose. • If not resolved within 4 weeks, permanently discontinue MEKTOVI.
• Grade 3 or Grade 4	Permanently discontinue MEKTOVI.
Hepatotoxicity
• Grade 2 AST or ALT increased	Maintain MEKTOVI dose. • If no improvement within 2 weeks, withhold MEKTOVI until improved to Grade 0-1 or to pretreatment/baseline levels and then resume at the same dose.
• Grade 3 or 4 AST or ALT increased	See Other Adverse Reactions.
Rhabdomyolysis or Creatine Phosphokinase (CPK) elevations
• Grade 4 asymptomatic CPK elevation or • Any Grade CPK elevation with symptoms or with renal impairment	Withhold MEKTOVI dose for up to 4 weeks. • If improved to Grade 0-1 resume at a reduced dose. • If not resolved within 4 weeks, permanently discontinue MEKTOVI.
Dermatologic [other than palmar plantar erythrodysesthesia syndrome (PPES)]
• Grade 2	If no improvement within 2 weeks, withhold MEKTOVI until Grade 0-1. Resume at same dose if first occurrence or reduce dose if recurrent.
• Grade 3	Withhold MEKTOVI until Grade 0-1. Resume at same dose if first occurrence or reduce dose if recurrent.
• Grade 4	Permanently discontinue MEKTOVI.
Other Adverse Reactions (including Hemorrhage)†
• Recurrent Grade 2 or • First occurrence of any Grade 3	Withhold MEKTOVI for up to 4 weeks. • If improves to Grade 0-1 or to pretreatment/baseline levels, resume at reduced dose. • If no improvement, permanently discontinue MEKTOVI.
• First occurrence of any Grade 4	Permanently discontinue MEKTOVI, or Withhold MEKTOVI for up to 4 weeks. • If improves to Grade 0-1 or to pretreatment/baseline levels, then resume at a reduced dose. • If no improvement, permanently discontinue MEKTOVI.
• Recurrent Grade 3	Consider permanently discontinuing MEKTOVI.
• Recurrent Grade 4	Permanently discontinue MEKTOVI.

Refer to the encorafenib prescribing information for dose modifications for adverse reactions associated with encorafenib.

Dosage Modifications for Moderate or Severe Hepatic Impairment

For patients with moderate (total bilirubin greater than 1.5 and less than or equal to 3 × ULN and any AST) or severe (total bilirubin levels greater than 3 × ULN and any AST) hepatic impairment, the recommended dosage is 30 mg orally taken twice daily.

Frequently asked questions

What is Mektovi used to treat?

More about Mektovi (binimetinib)

Patient resources

Mektovi drug information

Professional resources

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

Pregnancy & Lactation Risk data available

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

Review this drug

Mektovi Dosage

Patient Selection

Dosage Modifications for Adverse Reactions

Dosage Modifications for Moderate or Severe Hepatic Impairment

Frequently asked questions

More about Mektovi (binimetinib)

Patient resources

Professional resources

Related treatment guides

See also:

Opdivo Qvantig

Rybrevant

Enhertu

Opdivo

Keytruda

Avastin

Tagrisso

Trametinib

Docetaxel

Nivolumab

Further information